Coenzyme Q10 as Treatment for Long Term COVID-19

Coenzyme Q10 as Treatment for Long Term COVID-19

This study is a randomized, placebo-controlled, double-blinded, cross-over designed clinical trial investigating the effect of high-dose Coenzyme Q10 treatment in subjects with persisting symptoms more than 12 weeks af SARS-CoV-2 infection, Long Term COVID-19 (LTC).

The aim is to investigate the effect of high-dose Coenzyme Q10 on number and severity of self-reported symptoms in patients with Long Term COVID-19.

The study will be conducted at the Department of Infectious Diseases, Aarhus University Hospital in the LTC Outpatient Clinic. 120 study participants will be randomized 1:1 to receive placebo or CoQ10 in a dose of 500mg/day for 6 weeks. After a wash-out period of 4 weeks, participants are allocated to the opposite treatment for 6 weeks. The EQ-5D-5L and an LTC-specific questionnaire are completed at baseline and after 6,10,16, and 20 weeks. At each of 5 visits blood samples will be collected from the participants for immunological investigations and assessment of cellular metabolism.

Inclusion Criteria:

• Age above 18 years.
• Able to give informed consent.
• History of documented SARS-CoV-2 infection either by RT-PCR or antibody test.
• Symptoms related to Long Term COVID-19, defined as being investigated, diagnosed and followed by specialized infectious diseases physicians in the Long Term COVID-19 Outpatient Clinic, Central Region of Denmark, Aarhus University Hospital.
• Symptoms not attributable to other co-morbidity/condition.

Exclusion Criteria:

• Symptoms of acute COVID-19, as defined by The Danish Health Authorities.
• Women who are pregnant or breastfeeding, or with a positive pregnancy test as determined by a positive urine beta-human chorionic gonadotropin test during screening
• Hypersensitivity to the active ingredient or to any excipient of the medicinal product
• Known allergy to soy or peanuts.
• Individuals with reduced kidney or liver-function.
• Patients in anticoagulant therapy with vitamin K antagonists.
• Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy.